Non-Sponsored Content
Dasatinib FDA approved in paediatric patients with chronic phase Ph+ CML
By: News Feed | Last updated: 9th November 2017 | In: US FDA Onc\Haem Approvals
Article Keywords
BMS, Bristol-Myers Squibb, chronic phase, CML, CP, dasatinib, FDA, Ph+, Philadelphia chromosome, Sprycel
On 9 November 2017, the FDA granted regular approval to dasatinib (Sprycel®, Bristol-Myers Squibb) for the treatment of paediatric patients with chronic phase (CP) Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML).
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE
Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients
© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!